GET DAILY SIGNALSBioRestorative Therapies (BRTX): Stem Cell Pipeline and Regenerative Focus
Key Takeaways
- BRTX is the Nasdaq ticker for BioRestorative Therapies, Inc., a clinical-stage regenerative medicine and biotechnology company focused on adult stem cell therapies.
- The company's lead candidate, BRTX-100, is an autologous (patient-derived) mesenchymal stem cell therapy in Phase 2 development for chronic lower back pain caused by degenerative disc disease.
- BioRestorative operates through three main areas: a disc/spine program (BRTX-100), a metabolic program (ThermoStem®), and a commercial biocosmeceutical (regenerative skincare) platform.
- Headquartered in Melville, New York, the company has a small workforce and generates only modest revenue, primarily from its biocosmeceutical products, while remaining largely pre-revenue in its clinical programs.
- As a clinical-stage biotechnology company, BRTX carries significant risks tied to clinical trial outcomes, regulatory approval, and ongoing capital needs.
Introduction
BRTX represents the Nasdaq-listed common stock of BioRestorative Therapies, Inc., a biotechnology company developing therapeutic products and medical therapies built around adult stem cells. Investors track the company because it sits at the intersection of several large medical and commercial markets — chronic back pain, metabolic disease, and regenerative aesthetics — while still being in an early, clinical development stage. Understanding the company's pipeline, its business model, and its financial profile is essential before evaluating its long-term market position.
Company Background
BioRestorative Therapies, Inc. traces its origins to 1997 and was formerly known as Stem Cell Assurance, Inc. before adopting its current name in August 2011. The company reincorporated from Delaware to Nevada in December 2022 and is headquartered in Melville, New York. It operates as a single reporting segment within the healthcare and biotechnology sector.
The company's business model centers on developing cell-based therapies using its own cell and tissue protocols, primarily involving adult stem cells. Its work is organized across three core programs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
- Disc/Spine Program (brtxDISC™): The company's lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from a patient's own bone marrow. The therapy is intended for the non-surgical treatment of painful lumbosacral disc disorders, including chronic lower back pain arising from degenerative disc disease, or as a complementary therapy to surgery. The product is in Phase 2 clinical trials.
- Metabolic Program (ThermoStem®): This earlier-stage platform uses brown adipose (fat) derived stem cells to generate brown adipose tissue, with the goal of targeting obesity, type 2 diabetes, and other metabolic disorders. It represents a longer-term, pre-clinical/translational opportunity.
- BioCosmeceutical Platform: The company operates a commercial regenerative skincare business, manufacturing a cell-based secretome serum containing exosomes, proteins, and growth factors in a cGMP-compliant, ISO-7 certified clean room. This platform is currently the company's primary source of product revenue.
BioRestorative has also licensed an investigational curved needle device designed to deliver cells or other therapeutic material to the spine and discs. As a small company with roughly a dozen employees, it relies on a lean, research-intensive structure rather than a large commercial organization.
Why Investors Follow BRTX
BRTX attracts attention primarily because of its lead clinical program and the size of the markets it targets. Chronic lower back pain is a widespread condition, and a non-surgical, cell-based treatment alternative could represent a meaningful advance if BRTX-100 successfully completes clinical trials and gains regulatory approval. The company has reported preliminary blinded data from its Phase 2 trial, which it has described as consistent with its primary safety endpoint and showing encouraging early efficacy trends.
The ThermoStem® platform adds strategic optionality by addressing obesity and metabolic disease, large therapeutic areas with substantial unmet need. Meanwhile, the biocosmeceutical business gives the company a commercial revenue stream and a route to leverage its cell-manufacturing capabilities outside the clinical drug pathway.
From a financial and strategic standpoint, investors also track the company's partnerships and collaborations, its intellectual property portfolio, and its ability to fund operations through offerings and other financing. The company's "made-in-America" manufacturing approach and vertical control over cell sourcing and quality systems are positioned as competitive differentiators.
Risks and Important Considerations
Investing in BRTX involves substantial, biotechnology-specific risks. The company is clinical-stage, meaning its lead product has not yet been approved by the U.S. Food and Drug Administration (FDA). Clinical trials can fail, be delayed, or produce results that do not meet regulatory requirements, which could materially affect the company's prospects.
BioRestorative has a history of net losses and negative operating cash flow, and it relies on equity offerings and other financing to sustain its research and development. Its revenue remains minimal, concentrated largely in biocosmeceutical product sales, and it does not currently generate meaningful commercial income from its therapeutic candidates. The company is also exposed to competition from larger, better-capitalized biotechnology and pharmaceutical firms, as well as regulatory and manufacturing risks inherent to cell-based therapies. Investors should understand that the stock's valuation is closely tied to clinical milestones and capital-market access rather than established earnings.
Conclusion
BioRestorative Therapies stands out as a small, diversified regenerative medicine company with a lead cell therapy in Phase 2 clinical development, an earlier-stage metabolic program, and a commercial biocosmeceutical business. This combination of clinical pipeline and modest commercial activity distinguishes it from many single-asset biotechs, while its small size and pre-profit financial profile underscore the speculative nature of the stock. For investors, BRTX remains a high-risk, high-uncertainty name whose long-term relevance will depend heavily on clinical data, regulatory progress, and the company's ability to fund its programs over time.
Using AI Tools for Research
In my analysis of clinical-stage names like this, I often rely on Tickeron's AI Screener to quickly filter opportunities based on technical indicators, fundamentals, and sector trends. It helps narrow down ideas efficiently when evaluating biotech pipelines alongside broader market themes, allowing a more structured approach to screening without sifting through thousands of tickers manually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BRTX sees its Stochastic Oscillator ascending out of oversold territory
On October 29, 2026, the Stochastic Oscillator for BRTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 71 instances where the indicator left the oversold zone. In 59 of the 71 cases the stock moved higher in the following days. This puts the odds of a move higher at over 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on BRTX as a result. In 77 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for BRTX just turned positive on October 07, 2026. Looking at past instances where BRTX's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
Following a +3.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRTX advanced for three days, in 181 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
BRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for BRTX moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for BRTX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.694) is normal, around the industry mean (3.498). P/E Ratio (-1.434) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.055) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. BRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement